Drug intelligence / Profile preview

eicosapentaenoic acid + gamma-linolenic acid

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Enteral, Intravenous
01

Overview

Eicosapentaenoic acid (EPA) + gamma-linolenic acid (GLA) is a combination of two polyunsaturated fatty acids—EPA, an omega-3 fatty acid primarily found in fish oil, and GLA, an omega-6 fatty acid found in plant seed oils such as borage and evening primrose. This combination is used as a dietary supplement to modulate inflammation. EPA inhibits the conversion of GLA to arachidonic acid (AA), thereby reducing the synthesis of pro-inflammatory AA metabolites while maintaining or enhancing anti-inflammatory effects mediated by DGLA-derived prostaglandins like PGE1[1][5]. The combination has been studied for its potential benefits in chronic inflammatory disorders (such as rheumatoid arthritis), dry eye disease, diabetic neuropathy, and acute lung injury[1][5][10]. Mechanistically, both EPA and GLA reduce the production of pro-inflammatory eicosanoids; EPA also blocks delta-5-desaturase activity to prevent excess AA formation[1]. Clinical studies suggest that this combination may improve symptoms related to inflammation without causing harmful increases in serum AA levels[1][5].

Other names
EPA + GLAeicosapentaenoic acid and gamma-linolenic acid combination
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PTGER (Prostaglandin E2 receptor)FADS1 (Fatty acid desaturase 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on eicosapentaenoic acid + gamma-linolenic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on eicosapentaenoic acid + gamma-linolenic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call